{"id":"an2690","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL443052","moleculeType":"Small molecule","molecularWeight":"151.93"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting KCNN4, AN2690 is thought to reduce the excitability of neurons and potentially alleviate symptoms associated with certain neurological disorders. However, the exact mechanism of action and therapeutic potential of AN2690 are still being investigated.","oneSentence":"AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:11:32.909Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of focal epilepsy"}]},"trialDetails":[{"nctId":"NCT00680095","phase":"PHASE1","title":"Cumulative Irritation Test","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-01-22","conditions":"Onychomycosis","enrollment":37},{"nctId":"NCT01302119","phase":"PHASE3","title":"Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":"Onychomycosis of Toenails","enrollment":604},{"nctId":"NCT01270971","phase":"PHASE3","title":"Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-12-01","conditions":"Onychomycosis of Toenails","enrollment":594},{"nctId":"NCT00680160","phase":"PHASE2","title":"Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-04-30","conditions":"Onychomycosis","enrollment":15},{"nctId":"NCT00679965","phase":"PHASE2","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-02-28","conditions":"Distal, Subungual Onychomycosis","enrollment":159},{"nctId":"NCT01278394","phase":"PHASE2","title":"Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-03","conditions":"Onychomycosis","enrollment":29},{"nctId":"NCT00679523","phase":"PHASE2","title":"Safety and Efficacy Study of Subjects With Onychomycosis of the Great Toenail","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-11","conditions":"Onychomycosis","enrollment":60},{"nctId":"NCT03405818","phase":"PHASE4","title":"An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-10-22","conditions":"Onychomycosis, Tinea Unguium","enrollment":55},{"nctId":"NCT00679770","phase":"PHASE2","title":"Study of Different Doses of a Novel Treatment for Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-06-30","conditions":"Distal, Subungual Onychomycosis","enrollment":28},{"nctId":"NCT00679601","phase":"PHASE2","title":"Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-03-31","conditions":"Onychomycosis","enrollment":20},{"nctId":"NCT00680134","phase":"PHASE2","title":"Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-06-30","conditions":"Onychomycosis","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AN2690","genericName":"AN2690","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AN2690 is a small molecule that acts as a selective and potent inhibitor of the sodium-activated potassium channel, KCNN4. Used for Treatment of focal epilepsy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}